Funding
← Back to your selection

T. Rowe Price Investment Management

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Enterprise software · Jan 1, 2026
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$730M
2 disclosed · full round size, not this investor’s share

By stage

Series B1
Series C+1

By primary sector

Biotech1
Hardware1

By country

United States2

Rounds

2 in this selection
Ollin Biosciences

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B
Role not disclosed
SiFive

SiFive licenses RISC-V processor intellectual property for custom computing chips, including high-performance data-centre designs.

$400MSeries G
Role not disclosed